Actively Recruiting
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
Led by University of Washington · Updated on 2022-03-18
1800
Participants Needed
1
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.
CONDITIONS
Official Title
SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection
Who Can Participate
Eligibility Criteria
You may qualify if you...
- English speaking
- Have access to the internet (via computer or phone) on at least a weekly basis
- Asymptomatic (no symptoms requiring immediate treatment)
You will not qualify if you...
- Urogenital symptoms consistent with a sexually transmitted infection except vaginitis from trichomonas, bacterial vaginosis, or yeast
- Symptoms of cervicitis, urethritis, or pelvic inflammatory disease
- Antibiotic use within the last 2 weeks
- Contact with syphilis
- Contact with an STI and unwilling to wait for test results before treatment
- Receiving gonococcal-active drugs such as doxycycline, penicillin, or ceftriaxone during the visit
- Known allergy to ciprofloxacin or ceftriaxone
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Public Health -- Seattle & King County Sexual Health Clinic
Seattle, Washington, United States, 98104
Actively Recruiting
Research Team
A
Angela LeClair
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here